Biosensors

Biosensors: Barclays starts at Overweigth with TP $1.50. This comes on the back of Deutsche highlighting yday that Biosensors' share buyback has been providing support to the share price. Recall earlier this wk, Kalorama, a healthcare mkt research publisher, painted a positive backdrop for the US$5b drug eluting stent (DES) market, saying there is growing acceptance of DES as a more effective treatment for coronary heart disease, along with increasing awareness about coronary stents among patients, which should boost procedural volumes.